<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120337</url>
  </required_header>
  <id_info>
    <org_study_id>2018-103</org_study_id>
    <nct_id>NCT04120337</nct_id>
  </id_info>
  <brief_title>Safe Access: Trial With RemovAid Device</brief_title>
  <official_title>Safe Access: Randomized Trial to Compare Removal Techniques for the One-Rod Subdermal Contraceptive Implant: RemovAid Device Versus Standard Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemovAid AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mulago Hospital, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RemovAid AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial will compare different approaches to removing a subdermal contraceptive
      implant from the upper arm of 225 women in Uganda. The experimental approach is a hand-held
      device (RemovAid) that incises the skin and grasps the implant for extraction. Safety and
      efficacy endpoints will be compared to the traditional removal approach (scalpel, forceps,
      tweezers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial assigns participants to one of three arms: RemovAid+lidocaine patch (n=75),
      RemovAid+lidocaine injection (n=75) or traditional approach+lidocaine injection(n=75).
      Complication rates in the different arms will be compared. Efficacy (successful implant
      removal) will be the secondary comparisons. Finally, pain during removal and duration of
      removal procedure will be compared. Participants will return to the clinic within 4 weeks of
      the removal procedure to record the healing process and final interventions (if any).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who have post-removal complications</measure>
    <time_frame>4 weeks</time_frame>
    <description>Complications will include unusual level of trauma to the skin (bruising/hematoma), excessive bleeding, use of sutures to repair skin after removal, inability to remove the implant, implant breakage or severing at time of removal, subsequent infection at the removal site, and other complications that may be noted by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of removal</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Complete extraction of implant without breaking the product and without the need for additional tools such as a scalpel, tweezers, or forceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant pain level</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Level of pain as recorded on 10cm visual analog scale from 0cm (No Pain) to 10cm (Worse Pain Imaginable) with higher numbers indicating worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of removal procedure</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Number of minutes and seconds need to remove the implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider feedback on device on whether RemovAid device helped with removal of implant</measure>
    <time_frame>0-3 hours</time_frame>
    <description>5-point Likert scale measuring from 1(Strongly Disagree), 2 (Disagree), 3 (Neutral), 4 (Agree), 5 (Strongly Agree) on whether RemovAid device helped with removal of implant with higher scores indicating better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider feedback on device on ways the product helped or hindered implant removal</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Text responses on ways the product helped or hindered implant removal</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Removal of a Contraceptive Subdermal Implant</condition>
  <arm_group>
    <arm_group_label>RemovAid Device + lidocaine patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test device with lidocaine patch for local anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RemovAid Device + lidocaine injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test device with lidocaine injection for local anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard removal technique + lidocaine injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RemovAid device + lidocaine patch</intervention_name>
    <description>The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.</description>
    <arm_group_label>RemovAid Device + lidocaine patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard technique + lidocaine injection</intervention_name>
    <description>Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.</description>
    <arm_group_label>Standard removal technique + lidocaine injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RemovAid device + lidocaine injection</intervention_name>
    <description>The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.</description>
    <arm_group_label>RemovAid Device + lidocaine injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  seeking voluntary removal of a one-rod subdermal implant

          -  willing to sign an informed consent document

          -  willing to be randomized to the new device vs. standard technique

          -  willing to follow-up at the study clinic for any subsequent removal-related
             complications

          -  willing to have any follow-up complications recorded and shared

          -  has an implant that is completely and easily palpable

          -  has an implant that is easily pinched and lifted

          -  no known allergies to skin preparation products or local anesthetics

        Exclusion Criteria:

          -  Implants that are not easily palpable

          -  Previous failed implant removal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gemzell-Danielsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Gemzell-Danielsson, MD, PhD</last_name>
    <phone>+46 8 51772128</phone>
    <email>Kristina.Gemzell@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kawempe Referral Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josaphat Byamugisha, MD</last_name>
      <phone>256772580330</phone>
      <email>jbyamugisha@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Levine JP, Sinofsky FE, Christ MF; Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception. 2008 Nov;78(5):409-17. doi: 10.1016/j.contraception.2008.06.016. Epub 2008 Sep 18.</citation>
    <PMID>18929739</PMID>
  </reference>
  <reference>
    <citation>Fraser IS. The challenges of location and removal of Implanon contraceptive implants. J Fam Plann Reprod Health Care. 2006 Jul;32(3):151-2.</citation>
    <PMID>16857065</PMID>
  </reference>
  <reference>
    <citation>Creinin MD, Kaunitz AM, Darney PD, Schwartz L, Hampton T, Gordon K, Rekers H. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception. 2017 Feb;95(2):205-210. doi: 10.1016/j.contraception.2016.07.012. Epub 2016 Jul 21.</citation>
    <PMID>27452317</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results and data will be archived in the Norwegian Social Science Data Services (NSD). Data will be made available after the primary results are published.</ipd_description>
    <ipd_time_frame>Within 24 months after trial completion</ipd_time_frame>
    <ipd_access_criteria>open</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04120337/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

